Positron’s Revolutionary Nuclear Medicine Device for Use in Both Cardiac and Oncology Sectors Gaining the Attention of Ind

INDIANAPOLIS--(BUSINESS WIRE)-- Positron Corporation (OTCBB:POSC) is a molecular imaging solutions company focused on Nuclear Cardiology states that its proprietary product line also includes unique solutions for the oncology community designed to enhance its position in this industry.

The Company's Nuclear Pharm-Assist®, an automated radiopharmaceutical dose dispensing device aims to greatly transform the way healthcare providers serve patients seeking care for numerous cardiac and cancer diseases.

The innovative device has been attracting significant new partners by streamlining the production, dispensing and delivery of radiopharmaceuticals.

"We believe Positron's dose dispensing device will revolutionize the way radiopharmaceuticals are compounded and distributed in the US and around the world. Positron's products, services and position in the marketplace provide an economical, efficient and regulatory compliant solution in the multibillion dollar per year radiopharmaceutical consumables industry," said Positron's CEO Patrick G. Rooney. "While most in the industry already know that PET is the future of nuclear cardiology, we fully expect that an equal to greater amount of revenue and profits will be generated by our new proprietary automated radiopharmaceutical device as it is used in both the cardiac and oncology sectors."

Through automation procedures which are normally manually performed by technologists, pharmacists and staff, Positron's platform is able to expedite and deliver difficult to handle and transport doses at medical treatment facilities of all sizes. At the same time, the Nuclear Pharm-Assist®, meets the strictest guidelines for radiation exposure and is designed as a platform for compliance with United States Pharmacopeia regulations (USP 797).

Next week, the Company is scheduled to address investors and discuss Positron and the nuclear medicine industry’s demand for its products and how current and future opportunities will significantly impact the industry and the Company.

Positron Corporation's Press Conference

When: May 5, 2010, 1:00 pm EDT

Where: NASDAQ MarketSite, 4 Times Square, New York, NY

RSVP required for building security: 212 699-0999 or [email protected]

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. As a prominent player in the cardiac imaging industry, Positron maintains associations and relationships with multiple industry associations including the Academy of Molecular Imaging, American College of Cardiology American Society of Nuclear Cardiology and Society of Nuclear Medicine. Positron founded in 1983, is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.



CONTACT:

Positron Corporation
Patrick G. Rooney, (317)576-0183

KEYWORDS:   United States  North America  Indiana  New York

INDUSTRY KEYWORDS:   Health  Cardiology  Hospitals  Medical Devices  Oncology  Radiology  Other Health  General Health

MEDIA:

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.